Non-Cochrane · intervention · PM41585592
Comparative success of platelet-rich fibrin and mineral trioxide aggregate in direct pulp capping and pulpotomy: a systematic review and meta-analysis.
Alkabazi Malik, Aldieb Ebtesam · Biomaterial investigations in dentistry · 2026 · PubMed · doi:10.2340/biid.v13.45302
Findings
12 findings
| Population | ||||
|---|---|---|---|---|
| Adults or children with pulpitis (reversible or irreversible) requiring direct pulp capping or pulpotomy | Platelet-rich fibrin (PRF), alone or combined with other materials | Mineral trioxide aggregate (MTA) | Clinical success (absence of symptoms, abnormal responses and radiographic signs) 6 months · Overall (common-effect model) | OR 0.77 [0.44, 1.34] GRADE not reported 7 studies · 436 participants |
| Adults or children with pulpitis (reversible or irreversible) requiring direct pulp capping or pulpotomy | Platelet-rich fibrin (PRF), alone or combined with other materials | Mineral trioxide aggregate (MTA) | Clinical success (absence of symptoms, abnormal responses and radiographic signs) 12 months · Overall (common-effect model) | OR 1.51 [0.94, 2.43] GRADE not reported 7 studies · 392 participants |
| Adults or children with pulpitis (reversible or irreversible) requiring direct pulp capping or pulpotomy | Platelet-rich fibrin (PRF), alone or combined with other materials | Mineral trioxide aggregate (MTA) | Clinical success (absence of symptoms, abnormal responses and radiographic signs) 12 months · Overall (random-effects model) | OR 1.5 [0.93, 2.43] 9 [-2, 18] per 100 Low Downgraded: risk of bias, imprecision 7 studies · 392 participants |
| Adults or children with pulpitis (reversible or irreversible) requiring direct pulp capping or pulpotomy | Platelet-rich fibrin (PRF), alone or combined with other materials | Mineral trioxide aggregate (MTA) | Clinical success (absence of symptoms, abnormal responses and radiographic signs) 6 months · Overall (random-effects model) Unresolved: the two extractors disagree on this row. | OR 0.72 [0.29, 1.78] -5 [-23, 6] per 100 Low Downgraded: imprecision 7 studies · 436 participants |
| Patients requiring direct pulp capping | Platelet-rich fibrin (PRF), alone or combined with other materials | Mineral trioxide aggregate (MTA) | Clinical success (absence of symptoms, abnormal responses and radiographic signs) 12 months · Procedure: pulp capping; Common-effect model | OR 1.45 [0.65, 3.2] GRADE not reported 4 studies · 212 participants |
| Patients requiring direct pulp capping | Platelet-rich fibrin (PRF), alone or combined with other materials | Mineral trioxide aggregate (MTA) | Clinical success (absence of symptoms, abnormal responses and radiographic signs) 6 months · Procedure: pulp capping; Random-effects model | OR 2.4 [0.53, 10.87] GRADE not reported 3 studies · 198 participants |
| Patients requiring direct pulp capping | Platelet-rich fibrin (PRF), alone or combined with other materials | Mineral trioxide aggregate (MTA) | Clinical success (absence of symptoms, abnormal responses and radiographic signs) 12 months · Procedure: pulp capping; Random-effects model | OR 1.44 [0.64, 3.22] GRADE not reported 4 studies · 212 participants |
| Patients requiring direct pulp capping | Platelet-rich fibrin (PRF), alone or combined with other materials | Mineral trioxide aggregate (MTA) | Clinical success (absence of symptoms, abnormal responses and radiographic signs) 6 months · Procedure: pulp capping; Common-effect model | OR 3.38 [1.1, 10.38] GRADE not reported 3 studies · 198 participants |
| Patients requiring pulpotomy | Platelet-rich fibrin (PRF), alone or combined with other materials | Mineral trioxide aggregate (MTA) | Clinical success (absence of symptoms, abnormal responses and radiographic signs) 6 months · Procedure: pulpotomy; Random-effects model | OR 0.41 [0.18, 0.93] GRADE not reported 4 studies · 238 participants |
| Patients requiring pulpotomy | Platelet-rich fibrin (PRF), alone or combined with other materials | Mineral trioxide aggregate (MTA) | Clinical success (absence of symptoms, abnormal responses and radiographic signs) 12 months · Procedure: pulpotomy; Common-effect model | OR 1.54 [0.85, 2.8] GRADE not reported 3 studies · 180 participants |
| Patients requiring pulpotomy | Platelet-rich fibrin (PRF), alone or combined with other materials | Mineral trioxide aggregate (MTA) | Clinical success (absence of symptoms, abnormal responses and radiographic signs) 6 months · Procedure: pulpotomy; Common-effect model | OR 0.36 [0.17, 0.76] GRADE not reported 4 studies · 238 participants |
| Patients requiring pulpotomy | Platelet-rich fibrin (PRF), alone or combined with other materials | Mineral trioxide aggregate (MTA) | Clinical success (absence of symptoms, abnormal responses and radiographic signs) 12 months · Procedure: pulpotomy; Random-effects model | OR 1.54 [0.85, 2.8] GRADE not reported 3 studies · 180 participants |
Included primary studies 9
Open in Studies| Study | Year | Also included by | Outcomes it informs here | Trial data |
|---|---|---|---|---|
| Keswani 2014 Comparative evaluation of platelet-rich fibrin and mineral trioxide aggregate as pulpotomy agents in permanent teeth with incomplete root… PMID:24767550 | 2014 | 2 other reviews | Clinical success (absence of symptoms, abnormal responses and radiographic signs) | not extracted yet |
| Kumar 2016 Comparative evaluation of platelet-rich fibrin, mineral trioxide aggregate, and calcium hydroxide as pulpotomy agents in permanent molars… PMID:27994420 | 2016 | 2 other reviews | Clinical success (absence of symptoms, abnormal responses and radiographic signs) | not extracted yet |
| Abuhashema 2025 Clinical and radiographic assessment of mineral trioxide aggregate with platelet rich fibrin as pulp capping biomaterials: a 12-month… PMID:40234535 | 2025 | this review only | Clinical success (absence of symptoms, abnormal responses and radiographic signs) | not extracted yet |
| Eid 2022 Effectiveness of Three Agents in Pulpotomy Treatment of Permanent Molars with Incomplete Root Development: A Randomized Controlled Trial. PMID:35326909 | 2022 | this review only | Clinical success (absence of symptoms, abnormal responses and radiographic signs) | not extracted yet |
| Manhas 2019 Biological approach in repair of partially inflamed dental pulp using second-generation platelet-rich fibrin and mineral trioxide… PMID:31710016 | 2019 | this review only | Clinical success (absence of symptoms, abnormal responses and radiographic signs) | not extracted yet |
| Patidar 2017 Clinical and radiographic comparison of platelet-rich fibrin and mineral trioxide aggregate as pulpotomy agents in primary molars. PMID:28914251 | 2017 | this review only | Clinical success (absence of symptoms, abnormal responses and radiographic signs) | not extracted yet |
| Shobana 2022 Efficacy of Platelet Rich Plasma and Platelet Rich Fibrin for Direct Pulp Capping in Adult Patients with Carious Pulp Exposure- A… PMID:35786576 | 2022 | this review only | Clinical success (absence of symptoms, abnormal responses and radiographic signs) | not extracted yet |
| Singh 2020 To Compare Mineral Trioxide Aggregate, Platelet-rich Fibrin, and Calcium Hydroxide in Teeth with Irreversible Pulpitis: A Clinical Study. PMID:33149501 | 2020 | this review only | Clinical success (absence of symptoms, abnormal responses and radiographic signs) | not extracted yet |
| Tiwari 2024 To Evaluate and Compare Platelet-rich Fibrin and Mineral Trioxide Aggregate as Direct Pulp Capping Agents in Primary Molars: A Randomized… PMID:39185252 | 2024 | this review only | Clinical success (absence of symptoms, abnormal responses and radiographic signs) | not extracted yet |
Overlap with other reviews
Reviews that include the same primary studies are not independent evidence. Shared counts match studies by PMID, DOI or NCT, and otherwise by author and year (a probable match). Only the non-Cochrane dental reviews have study lists, so overlap with Cochrane reviews is not counted yet.
Review question
| Element | Planned (methods) | Found (results) |
|---|---|---|
| Population | Adults or children with symptomatic or asymptomatic reversible or irreversible pulpitis requiring direct pulp capping or pulpotomy | Patients needing pulp capping (n=4 studies) or pulpotomy (n=5 studies); primary and permanent teeth; 5 to 45 years |
| Intervention | Platelet-rich fibrin alone or combined with other materials | PRF (alone or with MTA or Ca(OH)2) (n=9) |
| Comparison | Mineral trioxide aggregate | MTA (n=9); also Ca(OH)2, nano-hydroxyapatite, PRP in some trials |
| Outcomes | Success rate (absence of spontaneous pain, abnormal thermal response, tenderness, swelling or sinus tract, radiographic evidence) | Clinical success at 6 months (n=7 studies, 436 teeth) and 12 months (n=7 studies, 392 teeth) |
| Study designs | Randomized and non-randomized clinical trials | 8 RCTs and 1 non-randomized clinical trial |
| Timing | Minimum follow-up 6 months | Follow-up 6, 12 and up to 24 months |